First Shipments of Injection Devices Already Arrived in
U.K.
WINNERSH, England, July 3, 2020 /PRNewswire/ -- BD (Becton,
Dickinson and Company) (NYSE: BDX), a leading global medical
technology company, today announced the receipt of a large pandemic
order from the U.K. government for 65 million needles and syringes
to be delivered by mid-September 2020
to support the U.K. vaccination effort for COVID-19. The first
shipments of the injection devices arrived in the U.K. on
June 18 and provide the first element
of the government's COVID-19 and flu response plan.
Mike Fairbourn, vice president
and general manager of BD – U.K. and Ireland said, "With a 60-year history in
vaccine delivery, BD is committed to producing 65 million
high-quality vaccine injection devices to support the U.K. in
planning for a COVID-19 vaccination campaign. BD applauds the U.K.
government for its forward-thinking and coordinated approach in
planning for future COVID-19 needs. This device selection will help
ensure the maximum number of U.K. citizens get inoculated in the
fastest possible timeframe. We thank the government for its
partnership, and we look forward to continuing to work with all
levels of government in the U.K., as we partner together to respond
to the COVID-19 pandemic and support the re-setting of the National
Health Service as core health care work resumes."
Recognising the need to prepare early, the U.K. is among the
first governments in the world to secure vaccine injection devices
in support of a national COVID-19 vaccination campaign. BD
continues to advise governments around the world that the time to
act on injection devices is now to prepare for when a COVID-19
vaccine has been approved and is widely available. While many
annual vaccines come ready-to-deliver in prefilled syringes, due to
the rapid ramp up in production and speed necessary to deploy the
COVID-19 vaccination quickly, the new vaccine is anticipated to be
made available initially in single or multidose vials, which
require the use of separate needles and syringes to draw the
vaccine from the vial and administer it to patients.
BD is the largest manufacturer of injection devices in the
world, producing billions of syringes and needles annually through
its global manufacturing network. This commitment is the latest
effort in the company's multifaceted global response to this virus.
In addition to ramping up manufacturing of needles and syringes, BD
has been working closely with the National Health Service (NHS) and
other government agencies to expand access to diagnostic testing
and support treatment of COVID-19 patients. Through June, the
company has supplied health care providers globally with
approximately 48 million swabs for flu and COVID-19 testing, more
than 2.85 million COVID-19 rapid molecular diagnostic tests on the
BD MAX™ System and millions of products used in the treatment of
COVID-19 patients, including infusion pumps, infusion sets and
catheters. BD Biosciences instruments are also being used by
researchers around the world to better understand the human immune
response to COVID-19.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com.
Contacts:
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Corporate
Communication
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
Photo -
https://mma.prnewswire.com/media/1199912/BD_UK_Vaccine.jpg
Logo - https://mma.prnewswire.com/media/617615/BD_Logo.jpg